10:18 AM EST - HLS Therapeutics Inc. : Announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration yesterday voted unanimously (16-0) that Amarin Corporation plc provided sufficient evidence of efficacy and safety to support the approval of Vascepa® (icosapent ethyl) capsules for an indication and label expansion to reduce the risk of cardiovascular events in high risk patients based on results from the landmark REDUCE-IT™ cardiovascular outcomes trial. HLS Therapeutics Inc.
shares T.HLS are trading up $1.27 at $19.25.
